{"pmid":32474577,"title":"Diligent medical activities of a publicly designated medical institution for infectious diseases pave the way for overcoming COVID-19: A positive message to people working at the cutting edge.","text":["Diligent medical activities of a publicly designated medical institution for infectious diseases pave the way for overcoming COVID-19: A positive message to people working at the cutting edge.","Clin Infect Dis","Nagano, Tatsuya","Arii, Jun","Nishimura, Mitsuhiro","Yoshida, Naofumi","Iida, Keiji","Nishimura, Yoshihiro","Mori, Yasuko","32474577"],"journal":"Clin Infect Dis","authors":["Nagano, Tatsuya","Arii, Jun","Nishimura, Mitsuhiro","Yoshida, Naofumi","Iida, Keiji","Nishimura, Yoshihiro","Mori, Yasuko"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474577","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1093/cid/ciaa694","topics":["Prevention"],"weight":1,"_version_":1668341932722487297,"score":9.490897,"similar":[{"pmid":32442437,"title":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.","text":["The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.","Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs.","Pharmacol Ther","Tundo, G R","Sbardella, D","Santoro, A M","Coletta, A","Oddone, F","Grasso, G","Milardi, D","Lacal, P","Marini, S","Purrello, P","Graziani, G","Coletta, M","32442437"],"abstract":["Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs."],"journal":"Pharmacol Ther","authors":["Tundo, G R","Sbardella, D","Santoro, A M","Coletta, A","Oddone, F","Grasso, G","Milardi, D","Lacal, P","Marini, S","Purrello, P","Graziani, G","Coletta, M"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442437","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.pharmthera.2020.107579","keywords":["cancer","neurodegeneration","proteasome","proteasome inhibitors","sars-cov-2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667523504895950848,"score":73.4551},{"pmid":32475169,"title":"COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?","text":["COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?","J Diabetes Sci Technol","Fuchs, Julia","Hovorka, Roman","32475169"],"journal":"J Diabetes Sci Technol","authors":["Fuchs, Julia","Hovorka, Roman"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475169","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/1932296820929714","keywords":["covid-19","closed-loop","diabetes","diabetes technology","remote healthcare","telemedicine"],"topics":["Prevention"],"weight":1,"_version_":1668437835036753920,"score":63.812622},{"pmid":32274842,"title":"Keeping a cut above the coronavirus disease: surgical perspectives from a public health institution in Singapore during Covid-19.","text":["Keeping a cut above the coronavirus disease: surgical perspectives from a public health institution in Singapore during Covid-19.","ANZ J Surg","Ng, Aven Shan Hua","Chew, Min Hoe","Charn, Tze Choong","Wong, Merng Koon","Wong, Wai Keong","Lee, Lui Shiong","32274842"],"journal":"ANZ J Surg","authors":["Ng, Aven Shan Hua","Chew, Min Hoe","Charn, Tze Choong","Wong, Merng Koon","Wong, Wai Keong","Lee, Lui Shiong"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274842","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1111/ans.15904","locations":["Singapore"],"countries":["Singapore"],"countries_codes":["SGP|Singapore"],"topics":["Prevention"],"weight":1,"_version_":1666138491660009473,"score":54.846153},{"pmid":32439289,"title":"Active smoking and COVID-19: a double-edged sword.","text":["Active smoking and COVID-19: a double-edged sword.","Eur J Intern Med","Lippi, Giuseppe","Sanchis-Gomar, Fabian","Henry, Brandon Michael","32439289"],"journal":"Eur J Intern Med","authors":["Lippi, Giuseppe","Sanchis-Gomar, Fabian","Henry, Brandon Michael"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439289","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ejim.2020.04.060","keywords":["covid-19","cigarette","coronavirus","smoking"],"topics":["Mechanism"],"weight":1,"_version_":1667523504805773312,"score":50.117027},{"pmid":32486618,"title":"Impact of the coronavirus disease 2019 pandemic on postgraduate medical education in a Singaporean academic medical institution.","text":["Impact of the coronavirus disease 2019 pandemic on postgraduate medical education in a Singaporean academic medical institution.","Korean J Med Educ","Sia, Ching-Hui","Tan, Benjamin Yong-Qiang","Ooi, Shirley Beng Suat","32486618"],"journal":"Korean J Med Educ","authors":["Sia, Ching-Hui","Tan, Benjamin Yong-Qiang","Ooi, Shirley Beng Suat"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486618","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3946/kjme.2020.157","locations":["Singaporean"],"countries":["Singapore"],"countries_codes":["SGP|Singapore"],"topics":["Prevention"],"weight":1,"_version_":1668623433640968193,"score":47.07282}]}